Skip to content. | Skip to navigation


Personal tools

Histology Core Publications

Peer-Reviewed Papers

2012

  • West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, Watson PH.Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2012 Nov 20. doi: 10.1038/bjc.2012.524. PMID: 23169287

  • Spowart JE, Townsend KN, Huwait H, Eshragh S, West NR, Ries JN, Kalloger S,Anglesio M, Gorski SM, Watson PH, Gilks CB, Huntsman DG, Lum JJ. The Autophagy Protein LC3A Correlates with Hypoxia and is a Prognostic Marker of Patient Survival in Clear Cell Ovarian Cancer. J Pathol. 2012 Aug 27. doi: 10.1002/path.4090.    PMID: 22926683

  • McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27. PMID: 22282309

  • Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012 Jun 15;18(12):3281-92. Epub 2012 May 2. PMID: 22553348. 

2011

  • West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126. Epub 2011 Dec 8. PMID: 22151962

  • West NR, Panet-Raymond V, Truong PT, Alexander C, Babinszky S, Milne K, Ross LA, Loken S, Watson PH. Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR). Breast Cancer (Auckl). 2011;5:105-15. Epub 2011 May 31. PMID: 21695097

2010

  • Webb JR, Wick DA, Nielsen JS, Tran E, Milne K, McMurtrie E, Nelson BH. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer. Gynecol Oncol. 2010 Sep;118(3):228-36. Epub 2010 Jun 11. PMID: 20541243

  • Martin ML, Wall EM, Sandwith E, Girardin A, Milne K, Watson PH, Nelson BH. Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model. Breast Cancer Res Treat. 2010 Jun;121(3):753-63. Epub 2009 Sep 30. PMID: 19789976

2009

  • Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009 Jul 29;4(7):e6412. PMID: 19641607

  • Yang T, Martin ML, Nielsen JS, Milne K, Wall EM, Lin W, Watson PH, Nelson BH. Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene. Cancer Immunol Immunother. 2009 Nov;58(11):1865-75. Epub 2009 Apr 7. PMID: 19350239

2008

  • Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS,Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M,Kalloger SE, Gilks CB, Watson PH, Nelson BH. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One. 2008;3(10):e3409. Epub 2008 Oct 15. PMID: 18923710

2007

  • Yang T, Wall EM, Milne K, Theiss P, Watson P, Nelson BH. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism. Clin Cancer Res. 2007 Dec 1;13(23):7172-80. PMID: 18056198

  • Wall EM, Milne K, Martin ML, Watson PH, Theiss P, Nelson BH. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res. 2007 Jul 1;67(13):6442-50.  PMID: 17616705